BioStem Technologies, Inc. (BSEM)
USD 8.3
(1.22%)
USD 8.3
(1.22%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 4.47 Million USD | 5.05% |
| 2022 | 4.31 Million USD | -3.87% |
| 2021 | 4.49 Million USD | -18.71% |
| 2020 | 5.52 Million USD | 11.07% |
| 2019 | 4.97 Million USD | 23.59% |
| 2018 | 4.02 Million USD | 343.65% |
| 2017 | 907.09 Thousand USD | 24.47% |
| 2016 | 728.74 Thousand USD | 727.12% |
| 2015 | 88.1 Thousand USD | -40.83% |
| 2014 | 148.89 Thousand USD | 809.12% |
| 2013 | 16.37 Thousand USD | 135.38% |
| 2012 | -46.29 Thousand USD | -76.84% |
| 2011 | -26.18 Thousand USD | 1.87% |
| 2010 | -26.68 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -2.34 Million USD | -154.1% |
| 2024 Q1 | 3.71 Million USD | -18.04% |
| 2023 Q2 | 5.48 Million USD | 12.72% |
| 2023 Q3 | 5.91 Million USD | 7.77% |
| 2023 FY | 4.53 Million USD | 5.05% |
| 2023 Q4 | 4.53 Million USD | -23.32% |
| 2023 Q1 | 4.86 Million USD | 12.77% |
| 2022 Q3 | 3.94 Million USD | 7.52% |
| 2022 FY | 4.31 Million USD | -3.87% |
| 2022 Q4 | 4.31 Million USD | 9.55% |
| 2022 Q1 | 4.08 Million USD | -8.94% |
| 2022 Q2 | 3.66 Million USD | -10.37% |
| 2021 Q3 | 5.13 Million USD | -6.54% |
| 2021 FY | 4.49 Million USD | -18.71% |
| 2021 Q4 | 4.49 Million USD | -12.57% |
| 2021 Q1 | 5.54 Million USD | 0.36% |
| 2021 Q2 | 5.49 Million USD | -0.88% |
| 2020 Q3 | 5.53 Million USD | 3.28% |
| 2020 Q1 | 4.92 Million USD | -0.99% |
| 2020 Q4 | 5.52 Million USD | -0.16% |
| 2020 FY | 5.52 Million USD | 11.07% |
| 2020 Q2 | 5.35 Million USD | 8.79% |
| 2019 FY | 4.97 Million USD | 23.59% |
| 2019 Q4 | 4.97 Million USD | 0.0% |
| 2018 Q1 | 948.75 Thousand USD | 0.04% |
| 2018 FY | 4.02 Million USD | 343.65% |
| 2018 Q2 | 1.09 Million USD | 14.93% |
| 2017 Q1 | 935.97 Thousand USD | 28.44% |
| 2017 Q3 | 872.48 Thousand USD | -10.1% |
| 2017 Q4 | 948.42 Thousand USD | 8.7% |
| 2017 FY | 907.09 Thousand USD | 24.47% |
| 2017 Q2 | 970.49 Thousand USD | 3.69% |
| 2016 Q1 | 284.32 Thousand USD | 222.71% |
| 2016 Q4 | 728.74 Thousand USD | -13.72% |
| 2016 FY | 728.74 Thousand USD | 727.12% |
| 2016 Q2 | 370.4 Thousand USD | 30.27% |
| 2016 Q3 | 844.59 Thousand USD | 128.02% |
| 2015 Q1 | -31.89 Thousand USD | -121.42% |
| 2015 Q2 | -52.46 Thousand USD | -64.49% |
| 2015 Q4 | 88.1 Thousand USD | 151.9% |
| 2015 Q3 | -169.74 Thousand USD | -223.54% |
| 2015 FY | 88.1 Thousand USD | -40.83% |
| 2014 Q4 | 148.89 Thousand USD | 263.95% |
| 2014 Q1 | 34.95 Thousand USD | 113.44% |
| 2014 Q2 | 24.19 Thousand USD | -30.78% |
| 2014 Q3 | 40.91 Thousand USD | 69.07% |
| 2014 FY | 148.89 Thousand USD | 809.12% |
| 2013 Q1 | 54.95 Thousand USD | 0.0% |
| 2013 Q2 | 102.5 Thousand USD | 86.52% |
| 2013 Q3 | 59.34 Thousand USD | -42.11% |
| 2013 Q4 | 16.37 Thousand USD | -72.4% |
| 2013 FY | 16.37 Thousand USD | 135.38% |
| 2012 FY | -46.29 Thousand USD | -76.84% |
| 2011 FY | -26.18 Thousand USD | 1.87% |
| 2010 FY | -26.68 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1310.00 USD | 341474.885% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 20.827% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 89.55% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 1891.528% |
| Rebus Holdings, Inc. | 305 Thousand USD | -1366.233% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 170.933% |
| Qrons Inc. | 351.42 Thousand USD | -1172.529% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 622.36 Thousand USD | -618.552% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 89.704% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 22013.029% |
| Skye Bioscience, Inc. | -5.72 Million USD | 178.163% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 71.63% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | -8.596% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -1012.859% |
| SQZ Biotechnologies Company | -36.23 Million USD | 112.341% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | -99.445% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | -382.321% |
| Mesoblast Limited | 55.85 Million USD | 91.994% |
| Marizyme, Inc. | 18.56 Million USD | 75.917% |
| Genus plc | 190.6 Million USD | 97.654% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | -100.016% |
| Pharming Group N.V. | 109.8 Million USD | 95.927% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | -419.856% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | -268.404% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | -557.649% |
| ContraFect Corporation | -6.02 Million USD | 174.212% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -3221.483% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | -287.043% |
| IMV Inc. | 7.67 Million USD | 41.699% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 18.719% |
| MultiCell Technologies, Inc. | 90.04 USD | -4966593.692% |
| ONE Bio Corp. | 9.04 Million USD | 50.531% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 709.284% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 65.456% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | -226.908% |
| Q BioMed Inc. | 4.06 Million USD | -10.148% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 85.364% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | -343.777% |
| Biomind Labs Inc. | 711.4 Thousand USD | -528.619% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 92.614% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | -123.669% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 65.08% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -1143.227% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -3098.772% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -22409.745% |
| Curative Biotechnology, Inc. | 2.2 Million USD | -103.09% |
| GB Sciences, Inc. | 1.74 Million USD | -155.936% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 2533.244% |
| HST Global, Inc. | 96.79 Thousand USD | -4520.18% |
| CSL Limited | 10.52 Billion USD | 99.958% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -2068.595% |
| Halberd Corporation | 144.72 Thousand USD | -2990.091% |
| Enzolytics Inc. | 981.65 Thousand USD | -355.558% |
| Agentix Corp. | 37.63 Thousand USD | -11783.848% |
| Resverlogix Corp. | 6.45 Million USD | 30.677% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 764.401% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -2.02 Billion USD | 100.22% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 109.512% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 36.755% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -65.103% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 150.589% |
| AVAX Technologies, Inc. | -5.9 Million USD | 175.756% |
| Zenith Capital Corp. | 10.06 Thousand USD | -44335.721% |
| Genscript Biotech Corporation | -1.06 Billion USD | 100.421% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -2131.186% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | -87.424% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -2618.399% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 24513.206% |
| Kadimastem Ltd | -253.1 Thousand USD | 1866.881% |
| Helix BioMedix, Inc. | -2.57 Million USD | 274.006% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 77.944% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -2122.073% |
| LadRx Corporation | -2.03 Million USD | 319.596% |
| Cell Source, Inc. | 9.23 Million USD | 51.56% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -604.069% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -604.069% |
| NovAccess Global Inc. | 2.17 Million USD | -105.283% |
| Affymax, Inc. | -5.59 Million USD | 179.9% |
| Itoco Inc. | 228.3 Thousand USD | -1858.788% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -3188.509% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 9.784% |
| Mobile Lads Corp. | 484.23 Thousand USD | -823.527% |
| CytoDyn Inc. | 20.26 Million USD | 77.929% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 691291.808% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 48350.399% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 41.967% |
| SYBLEU INC | 473.71 Thousand USD | -844.032% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | -0.336% |
| International Stem Cell Corporation | 2.59 Million USD | -72.665% |
| Bioxytran, Inc. | 1.89 Million USD | -135.504% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -7065.192% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -105.053% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | -30.227% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 47.714% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | -478.821% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 457.761% |
| Neutra Corp. | 52.18 Thousand USD | -8469.205% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 279.671% |
| PureTech Health plc | -167.19 Million USD | 102.675% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 1925.996% |
| IXICO plc | -4.44 Million USD | 200.617% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 66.17% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 91.847% |
| CSL Limited | 10.52 Billion USD | 99.958% |
| Cellectis S.A. | -43.81 Million USD | 110.206% |